

15 April 2022

Incidence and Treatment of Oesophageal and Gastric Cancer

Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:

- **CAPOX (Capecitabine with Oxaliplatin) :0**
- **FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) :0**
- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) :0**
- **Any other systemic anti-cancer therapy :**
 - CX 60/625 : 5**
 - CX 60/625 & Trast : <5**
 - FLOT: 7**
 - Nivolumab 480mg MSI-H : <5**
 - OX 80/375 : 6**
 - OX 80/375 Trast: <5**
- **Palliative care only Not available in RISOH query field**

Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:

- **Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) : <5**
- **Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) : 40**
- **Nivolumab monotherapy : <5**
- **Nivolumab and Ipilimumab : 0**
- **Any other systemic anti-cancer therapy**
 - Docetaxel : <5**
 - EtopCarbo: <5**
 - FLOT: 28**
 - GemCarb: <5**
 - IMDG: 5**
 - Ramuc & Pac: <5**
 - WeeklyCis+XRT: <5**
 - WeeklyCarb XRT : <5**
 - Weekly Pac/CarbXRT: <5**
- **Palliative care only Not available in RISOH query field**

15 April 2022

Q3. Of the Oesophageal Cancer patients (from Q2) treated with Pembrolizumab in the past 3 months, how many patients were treated for:

- Oesophageal adenocarcinoma : <5
- Oesophageal squamous cell carcinoma : <5

Q4. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with:

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) : <5
- Platinum and Fluoropyrimidine based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) : 31
- Nivolumab monotherapy : <5
- Nivolumab and Ipilimumab : 0
- Any other systemic anti-cancer therapy
- Docetaxel : <5
- EtopCarbo: <5
- FLOT: <5
- GemCarb: <5
- IMDG: 5
- Ramuc & Pac: <5
- WeeklyCis+XRT: <5
- Weekly Pac/CarbXRT: <5
- Palliative care only Not available in RISOH query field

Q5. Of the advanced/metastatic oesophageal cancer patients (from Q4) treated in the past 3 months, how many patients were treated for:

- Advanced/metastatic oesophageal adenocarcinoma : 34
- Advanced/metastatic oesophageal squamous cell carcinoma :15

15 April 2022

Q6. Does your trust participate in any active clinical trials for the treatment of oesophageal cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Title acronym	Full Title	TOTAL study recruitment
OCCAMS	Oesophageal Cancer Clinical and Molecular Stratification Study (OCCAMS) - A Multi-Centre study to determine predictive and prognostic biomarkers and therapeutic targets for oesophageal and junctional adenocarcinoma including whole genome sequencing	131
SCOPE 2	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	7
PLATFORM	Planning treatment for oesophago-gastric cancer: a randomised maintenance therapy trial (PLATFORM Trial)	< 5
ICHOR	Investigation of Circulating Haematological Biomarkers in Cancer	16
REGAL	Capturing trastuzumab REsistance in Gastroesophageal Adenocarcinoma by Liquid biopsy	In-set-up